Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Type 2 Issues Archives
Print | Email | Share | Comments (0)

Limiting Body's Response to Glucagon Holds Promise for Type 2s

Dec 1, 2000

Receptor-clogging Compound Controls Glucose Levels in Rats

Normally a stranger to such parts, diabetes was at the top of the marquee at this year's American Chemical Society, held in Washington, D.C. Three studies conducted by pharmaceutical companies revealed potential for glucagon-receptor-blocking compounds as a means of controlling type 2 diabetes.

The first study sought to control glucose levels in rats by using a compound to lower their bodies' response to glucagon, a hormone that raises blood sugar levels when they get too low. The result of cooperative research between Danish and American pharmaceutical companies, the compound is designed to block glucagon receptors. Rats were injected with either the compound or a placebo, then given intravenous glucose 15 minutes later. The animals given the placebo demonstrated between two and four times the level of blood glucose as those whose glucagon receptors had been blocked.

A second study, conducted by the same cooperative working group, gave rats abdominal injections of a different version of the compound, with similar reductive effects on glucose levels.

Danish pharmaceutical giant Novo Nordisk tested its own oral version of the compound. In their study, rats given the compound maintained steady blood sugar levels, even after being injected with glucagon.

No human trials appear to be in the works as of yet, but effectively controlling the body's reception of glucagon is being hailed by many researchers as a potential alternative to current type 2 drugs.


Categories: Blood Glucose, Blood Sugar, Diabetes, Diabetes, Novo Nordisk, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.